Axsome Therapeutics to Participate in Upcoming Investor Conferences

Core Viewpoint - Axsome Therapeutics is actively participating in two investor conferences in March 2025, showcasing its commitment to advancing treatments for central nervous system disorders [1][4]. Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on treating central nervous system (CNS) conditions, with a portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine [2]. - The company aims to address significant gaps in care by developing differentiated products that lead to meaningful advancements in patient outcomes, impacting over 150 million people in the United States [2]. Upcoming Events - The company will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 9:50 a.m. ET in Boston, MA [4]. - Additionally, Axsome will present at the Leerink Partners Global Biopharma Conference on March 12, 2025, at 10:40 a.m. ET in Miami, FL [4].